Target intelligence / Profile preview

Complement component 1q (C1q) (C1q)

Target
C1q
Molecular classification
Other (pattern-recognition molecule of the complement system), Receptor–ligand system component (recognition subcomponent of the C1 complex), Innate immune effector (classical complement pathway initiator)
01

Overview

Complement component 1q (C1q) is the recognition subcomponent of the C1 complex that initiates the classical complement pathway of the innate immune system. It binds antigen–antibody complexes—principally IgM and IgG subclasses except IgG4—thereby activating the associated serine proteases C1r and C1s to trigger downstream complement activation[1]. Structurally, C1q is a ~460 kDa hexamer composed of 18 chains (six each of A, B, and C) forming six collagen-like heterotrimers that converge into a central stalk with six C-terminal globular heads (gC1q); the A, C, and B genes (C1QA, C1QC, C1QB) are clustered on chromosome 1 in A–C–B order[1][7][3]. The gC1q domain is a heterotrimeric β-sandwich with a Ca2+-binding site that underpins versatile ligand recognition and Ca2+-dependent interactions with C1r/C1s in the assembled C1 complex[8][6][2]. Beyond complement activation, C1q functions as a pattern-recognition molecule binding diverse self and non-self ligands (e.g., microbial surfaces, apoptotic cells, phosphatidylserine, CRP) and engages cell receptors to regulate phagocytosis and immune signaling, with additional roles described in CNS aging and tumor biology[7][5][4].

Other names
Complement C1qC1q complexC1qA/C1qB/C1qC chainsC1q globular head (gC1q)
02

Mechanism of action

For ligands that activate C1q: multivalent binding of gC1q to clustered Fc regions on IgM/IgG immune complexes triggers conformational changes that enable Ca2+-dependent assembly/activation of C1r–C1s within C1, leading to cleavage of C4 and C2 and formation of C3 convertase (C4b2a). For non-complement interactions: gC1q binding to ligands/receptors modulates cellular responses (e.g., phagocytosis via calreticulin–CD91; integrin-mediated effects).

03

Biological functions

Initiation of the classical complement pathway via binding to antigen–antibody complexes and activating C1r and C1sPattern recognition of self, non-self, and altered-self ligands (e.g., microbes, apoptotic cells, phosphatidylserine, CRP)Opsonization and clearance of immune complexes and cell debrisModulation of immune cell functions via interactions with cell-surface receptors (e.g., calreticulin–CD91, integrin α2β1)Non-complement roles in tissue homeostasis and development, including effects in the CNS and aging
04

Disease associations

Autoimmunity (deficiency associated with systemic lupus erythematosus risk; immune tolerance roles)Infection (host defense; pathogen recognition)Neurodegenerative/neurological disease and aging-related CNS changesCancer/tumor biology modulation (reported regulatory roles)Inflammation (central mediator via complement activation)
05

Safety considerations

Broad immunomodulatory role raises risk of infection or impaired immune complex clearance if directly inhibited (on-target immunosuppression)Potential impacts on tissue homeostasis and CNS functions given non-complement roles, implying possible neuro or tissue effects with modulationCalcium-dependent assembly and multi-ligand binding suggest off-target/complex pharmacology challenges for drug design
06

Interacting drugs

Antibodies and Ig classes (IgM, IgG1–3 but not IgG4)

1 more in the full profile.

07

Biomarkers

Serum C1q levels or activity as indicators of classical pathway function and in autoimmune contexts (e.g., SLE)Anti-C1q antibodies (often explored in lupus)

Beyond the preview

Go deeper on Complement component 1q (C1q) (C1q).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Complement component 1q (C1q) (C1q).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call